biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
327, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
mouse, human, rat
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
dilution
(Immunoblotting (2.5 µg/mL)
Immunoprecipitation (1 µg antibody)
Frozen Sections (not recommended)
Immunofluorescence (not recommended)
Paraffin Sections (not recommended))
isotype
IgG1
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... SRC(6714)
General description
Purified mouse monoclonal generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with P3X63 Ag8.653 myeloma cells (see application references). Recognizes the ~60 kDa Src protein.
Recognizes the ~60 kDa v-Src and c-Src proteins in NIH/3T3 and HT1080 cells. May appear as a doublet due to phosphorylation.
This Anti-v-Src (Ab-1) Mouse mAb (327) is validated for use in Immunoblotting, Immunoprecipitation, Frozen Sections, Immunofluorescence, Paraffin Sections for the detection of v-Src (Ab-1).
Immunogen
Epitope: within the SH3 domain of v-Src and c-Src
purified v-Src
Application
Immunoblotting (2.5 µg/ml, see application references)
Immunoprecipitation (1 µg antibody or use Cat. No. OP07A; see application references)
Frozen Sections (not recommended)
Immunofluorescence (not recommended)
Paraffin Sections (not recommended)
Immunoprecipitation (1 µg antibody or use Cat. No. OP07A; see application references)
Frozen Sections (not recommended)
Immunofluorescence (not recommended)
Paraffin Sections (not recommended)
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.4.
Analysis Note
Positive Control
NIH/3T3 cells
NIH/3T3 cells
Other Notes
Courtneidge, S.A. and Heber, A. 1987. Cell50, 1031.
Cartwright, C.A., et al. 1985. Mol. Cell. Biol.5,, 2647.
Courtneidge, S.A. 1985. EMBO J.4, 1471.
Whitman, M., et al. 1985. Nature315, 239
Bolen, J.B., et al. 1984. Cell38, 767.
Hunter, T. and Sefton, B. 1980. Proc. Natl. Acad. Sci.77, 1311.
Collett, M.S. et al. 1979. Proc. Natl. Acad. Sci.76, 3159.
Collett, M.S. and Erikson, R.L. 1978. Proc. Natl. Acad. Sci.75, 2021.
Collett, M.S., et al. 1978. Cell15, 1363.
Cartwright, C.A., et al. 1985. Mol. Cell. Biol.5,, 2647.
Courtneidge, S.A. 1985. EMBO J.4, 1471.
Whitman, M., et al. 1985. Nature315, 239
Bolen, J.B., et al. 1984. Cell38, 767.
Hunter, T. and Sefton, B. 1980. Proc. Natl. Acad. Sci.77, 1311.
Collett, M.S. et al. 1979. Proc. Natl. Acad. Sci.76, 3159.
Collett, M.S. and Erikson, R.L. 1978. Proc. Natl. Acad. Sci.75, 2021.
Collett, M.S., et al. 1978. Cell15, 1363.
pp60src may appear as a doublet due to phosphorylation. This antibody can be used to precipitate active src kinase (see application references). The agarose conjugate, Cat. No. OP07A, is available separately for immunoprecipitation. Antibody should be titrated for optimal results in individual systems.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Soshi Noshita et al.
Journal of cell science, 136(15) (2023-07-13)
The non-receptor tyrosine kinase SRC is overexpressed and/or hyperactivated in various human cancers, and facilitates cancer progression by promoting invasion and metastasis. However, the mechanisms underlying SRC upregulation are poorly understood. In this study, we demonstrate that transforming growth factor-β
Lisa M Mehlmann et al.
Reproduction (Cambridge, England), 129(5), 557-564 (2005-04-28)
SRC family kinases (SFKs) function in initiating Ca2+ release at fertilization in several species in the vertebrate evolutionary line, but whether they play a similar role in mammalian fertilization has been uncertain. We investigated this question by first determining which
Arkadiusz Welman et al.
Neoplasia (New York, N.Y.), 8(11), 905-916 (2006-11-30)
The levels and activity of c-Src in colorectal cancer cells increase steadily during the course of colorectal carcinogenesis and are most highly elevated in advanced metastatic disease. However, the effects of increases in c-Src activity on the proliferation of colorectal
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| OP07-100UG | 04055977225006 |